Patterns of hormone replacement therapy in a population-based cohort of postmenopausal German women. Changes after HERS II and WHI

Experimental and Clinical Endocrinology and Diabetes

Volumn 113, Issue 9, 2005, Pages 529-533

  Clanget, Christof ^a   Hinke, V ^a   Lange, S ^b   Fricke, R ^b   Botko, R ^c   Pfeilschifter, J ^c  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c Ev Krankenhaus Lutherhaus   (Germany)

Author keywords

Epidemiology; Hormone replacement therapy; Hysterectomy; Menopause

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; FEMALE; GERMANY; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; MEDICAL RESEARCH; POSTMENOPAUSE; PRIORITY JOURNAL; PUBLICATION;

AGED; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; COHORT STUDIES; ESTROGENS; FEMALE; GERMANY; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PROGESTINS; QUESTIONNAIRES; RISK FACTORS; WOMEN'S HEALTH;

EID: 27744562545     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-865802     Document Type: Article

References (43)

1. Arzneimittelkommission der deutschen Ärzteschaft. Hormontherapie im Klimakterium. Arzneiverordnung in der Praxis 2003; 30: 1-40
2. Austin PC, Mamdani MM, Tu K, Jaakkimainen L. Prescriptions for estrogen replacement therapy in Ontario before and after publication of the Women's Health Initiative Study. JAMA 2003; 289: 3241-3242
3. Banks E, Barnes I, Baker K, Key TJ. Use of hormonal therapy for menopause in nine European countries. IARC Sci Publ 2002; 156: 301-303
4. Barrett-Connor E. Hormones and the health of women: past, present, and future. Keynote address. Menopause 2002; 9: 23-31
5. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998; 19: 55-72
6. Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-427
7. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003; 289: 3243-3253
8. Deutsche Gesellschaft für Gynäkologie und Geburtshilfe. Konsensus-empfehlungen zur Hormontherapie (HT) im Klimakterium und in der Postmenopause. Frauenarzt 2004; 45: 620ff
9. Goodman MT, Nomura AM, Wilkens LR, Kolonel LN. Agreement between interview information and physician records on history of menopausal estrogen use. Am J Epidemiol 1990; 131: 815-825
10. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-1037
11. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N, for the HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 49-57
12. Greendale GA, James MK, Espeland MA, Barrett-Connor E. Can we measure prior postmenopausal estrogen/progestin use? The Postmenopausal Estrogen/Progestin Interventions Trial. The PEPI Investigators. Am J Epidemiol 1997; 146: 763-770
13. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133: 933-941
14. Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med 2004; 140: 184-188
15. Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE, Aragaki AK, Shumaker SA, Brzyski RG, LaCroix AZ, Granek IA, Valanis BG. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003; 348: 1839-1854
16. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004; 291: 47-53
17. Hinke V, Clanget C, Botko R, Kallenbach S, Löscher S, Richter A, Schumacher J, Schatz H, Pfeilschifter J. The Bochum Postmenopause Study. Exp Clin Endocrinol Diabetes 2003; 111: A2
18. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E, for the Heart and Estrogen/progestin Replacement Study Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-613
19. Jannausch ML, Sowers MR. Consistency of perimenopausal estrogen use reporting by women in a population-based prospective study. Maturitas 1992; 14: 161-169
20. Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, Ayanian JZ. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 1999; 130: 545-553
21. Kopera H. [History of the hormonal treatment of climacteric disease symptoms]. Wien Med Wochenschr 1991; 141: 346-348
22. Lawton B, Rose S, McLeod D, Dowell A. Changes in use of hormone replacement therapy after the report from the Women's Health Initiative: cross sectional survey of users. BMJ 2003; 327: 845-846
23. Lundberg V, Tolonen H, Stegmayr B, Kuulasmaa K, Asplund K. Use of oral contraceptives and hormone replacement therapy in the WHO MONICA project. Maturitas 2004; 48: 39-49
24. Manson JE, Martin KA. Postmenopausal hormone-replacement therapy. N Engl J Med 2001; 345: 34-40
25. Oddens BJ, Boulet MJ, Lehert P, Visser AP. Has the climacteric been medicalized? A study on the use of medication for climacteric complaints in four countries. Maturitas 1992; 15: 171-181
26. Petitti DB. Hormone replacement therapy and heart disease prevention: experimentation trumps observation. JAMA 1998; 280: 650-652
27. Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, Gass ML, Stefanick ML, Lane DS, Hays J, Johnson KC, Coker LH, Dailey M, Bowen D. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289: 2663-2672
28. Schneider HP. Cross-national study of women's use of hormone replacement therapy (HRT) in Europe. Int J Fertil Womens Med 1997; 42 (Suppl 2): 365-375
29. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K, Coker LH. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004; 291: 2947-2958
30. Shumaker SA, Legault C, Rapp SR, Thai L, Wallace RB, Ockene JK, Hendrix SL, Jones BN, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S, Wactawski-Wende J. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289: 2651-2662
31. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20: 47-63
32. Stove J, Sturmer T, Kessler S, Brenner H, Puhl W, Gunther KP. Hysterectomy and patterns of osteoarthritis. The Ulm Osteoarthritis Study. Scand J Rheumatol 2001; 30: 340-345
33. Strothmann A, Schneider HP. Hormone therapy: the European women's perspective. Climacteric 2003; 6: 337-346
34. The North American Menopause Society. Amended report from the NAMS Advisory Panel on Postmenopausal Hormone Therapy. Menopause 2003; 10: 6-12
35. The North American Menopause Society. Recommendations for estrogen and progestogen use in peri- and postmenopausal women: Oktober 2004 Position Statement of The North American Menopause Society. http://www.menopause.org/ edumaterials/2004 HTreport.pdf. 2004; access date: 6-11-2004
36. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 1998; 19: 61-109
37. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273: 199-208
38. Thiel C, Heinemann LA, Assmann A. [Reasons for the change in HRT therapy from the perspective of women. Results of the German Cohort Study on Women's Health]. Zentralbl Gynakol 2001; 123: 390-398
39. Turgeon JL, McDonnell DP, Martin KA, Wise PM. Hormone therapy: physiological complexity belies therapeutic simplicity. Science 2004; 304: 1269-1273
40. US Preventive Services Task Force. Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: recommendations and rationale. Ann Intern Med 2002; 137: 834-839
41. van Keep PA. The history and rationale of hormone replacement therapy. Maturitas 1990; 12: 163-170
42. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, Kotchen T, Curb JD, Black H, Rossouw JE, Aragaki A, Safford M, Stein E, Laowattana S, Mysiw WJ. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003; 289: 2673-2684
43. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002; 288: 321-333